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OutcomeAbstract Background: Mesenchymal chondrosarcoma (MCS) is a distinct, very rare sarcoma
with little evidence supporting treatment recommendations.
Patients and methods: Specialist centres collaborated to report prognostic factors and out-
come for 113 patients.
Results: Median age was 30 years (range: 11–80), male/female ratio 1.1. Primary sites were
extremities (40%), trunk (47%) and head and neck (13%), 41 arising primarily in soft tissue.
Seventeen patients had metastases at diagnosis. Mean follow-up was 14.9 years (range:
1–34), median overall survival (OS) 17 years (95% conﬁdence interval (CI): 10.3–28.6).
Ninety-ﬁve of 96 patients with localised disease underwent surgery, 54 additionally received
combination chemotherapy. Sixty-ﬁve of 95 patients are alive and 45 progression-free (5 local
recurrence, 34 distant metastases, 11 combined). Median progression-free survival (PFS) and
OS were 7 (95% CI: 3.03–10.96) and 20 (95% CI: 12.63–27.36) years respectively. Chemother-
apy administration in patients with localised disease was associated with reduced risk of recur-
rence (P = 0.046; hazard ratio (HR) = 0.482 95% CI: 0.213–0.996) and death (P = 0.004;
HR = 0.445 95% CI: 0.256–0.774). Clear resection margins predicted less frequent local recur-
rence (2% versus 27%; P = 0.002). Primary site and origin did not inﬂuence survival. The
absence of metastases at diagnosis was associated with a signiﬁcantly better outcome
(P < 0.0001). Data on radiotherapy indications, dose and fractionation were insufﬁciently
complete, to allow comment of its impact on outcomes. Median OS for patients with metas-
tases at presentation was 3 years (95% CI: 0–4.25).
Conclusions: Prognosis in MCS varies considerably. Metastatic disease at diagnosis has the
strongest impact on survival. Complete resection and adjuvant chemotherapy should be con-
sidered as standard of care for localised disease.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Mesenchymal chondrosarcoma (MCS) accounts for
3–10% of all chondrosarcoma diagnoses and has distinc-
tive clinical features [1,2]. Morphologically, MCS is
characterised by a biphasic pattern of undiﬀerentiated
small blue round cells and islands of hyaline cartilage.
The small cell component shows positive staining for
SOX9 and negativity for FLI-1, which often helps in dif-
ferential diagnosis from Ewing sarcoma [3]. Recently,
the HEY1-NCOA2 fusion has been described in MCS,
a marker of diagnostic utility [4].
Axial skeleton and femur are the most common pri-
mary sites for skeletal MCS; soft tissue MCS may aﬀect
meninges and have visceral involvement [1,2,5,6]. Clini-
cal ﬁndings at diagnosis are usually swelling and pain.
Imaging features for MCS are more aggressive than
those of conventional chondrosarcoma: lesions show
lytic and destructive appearances, periosteal reaction is
poorly deﬁned, cortical breakthrough and extra-osseous
extension are common. Mottled calciﬁcation is present in
one-third of cases, sometimes extensive. Pathological
fracture is rare [7]. Few cases of MCS have been reported
to be positive using ﬂuorodeoxyglucose-positron emis-
sion tomography (FDG-PET) [8,9].
MCS shows a strong tendency towards late local and
metastatic recurrences. Despite a potentially prolonged
clinical course, the outcome for these patients ultimately
appears to be poor, with reported 10-year survival rate
in the range of 27–67% [1,9].Less than 600 cases of MCS have been published,
mainly as case reports or small case series, and we found
only three studies which include more than 20 patients
with follow-up data [1,2,10,11].
Given the rarity of MCS and the limitations of the
published reports, little evidence supports current treat-
ment recommendations. In particular the value of radio-
therapy and chemotherapy is poorly deﬁned. The
European Musculoskeletal Oncology Society (EMSOS)
has previously successfully drawn together the collective
experience of its members to illuminate uncommon
areas of practice [12–15]. We therefore used this resource
to investigate MCS, with the aim of describing current
practice and identifying predictive factors to provide
direction for potential prospective studies.2. Patients and methods
2.1. Data collection
EMSOS members were invited to contribute cases
to a review of patients diagnosed with MCS. The pro-
tocol synopsis and database were available on the
EMSOS website. Anonymised data for patient demo-
graphics, tumour, treatment, clinical course and out-
comes were obtained. Because of the rarity of this
condition we accepted that some of the patients in this
study will have been included in previous analyses, but
all follow-up data were updated [9,11]. Because
all participating centres were reference centres for
376 A.M. Frezza et al. / European Journal of Cancer 51 (2015) 374–381musculoskeletal oncology, radiology and histology of
the retrieved cases was not reviewed.
2.2. Statistical analysis
Descriptive analysis was made using median values
and 95% conﬁdence interval (CI). Diﬀerences between
groups were assessed using the Chi-squared test. The
Cox proportional hazards model was used to assess
the eﬀect on survival outcomes of origin (skeletal/extra-
skeletal), primary site (axial/extremity), margins (R0/
R1) and use of chemotherapy. Multivariate analysis
was performed using Cox’s proportional hazard method
with the inclusion of all the variables taken into account
for univariate analysis (origin, primary site, margins and
use of chemotherapy). Progression free survival (PFS) in
patients with localised disease was calculated as the per-
iod from surgery to the ﬁrst observation of disease
recurrence. Overall survival (OS) was calculated from
diagnosis to death or the last documented time the
patient was known to be alive. Patients with no evidence
of progression were censored at the last assessment.
Death was considered an event regardless of the cause.
Patients alive were censored at the last contact. Survival
analysis was done using Kaplan–Meier (KM) survivor-
ship. Signiﬁcance was set at P < 0.05 for two-sided tests.
SPSS software was used for statistical analysis.
3. Results
3.1. Patients population
Seventeen centres and one cooperative group contrib-
uted to this study, with 128 cases collected from 1971 to
2012. Fifteen patients had no staging details and/or fol-
low-up data, resulting in 113 patients available. Mean
follow-up was 14.9 years (range: 1–34). Male/female
ratio was 1.1:1 (60 males, 53 females). Median age at
diagnosis was 30 years (range: 11–80). Sixty-one patients
(61/113; 54%) were in the 2nd–3rd decade of life, 34/113
(30%) in the 4th–5th, 18/113 (16%) in the 6th–8th.
Seventy-two (72/113; 64%) tumours had a skeletal
origin, 41/113 (36%) arose from somatic soft tissue.Fig. 1. Distribution by age and gendeCraniofacial bones were aﬀected in 15/113 patients
(13%), trunk in 53/113 (47%), limbs in 45/113 (40%).
Distribution by age and gender (Fig. 1A), origin and pri-
mary site (Fig. 1B) are shown. Ninety-six (96/113; 85%)
patients had localised disease at presentation.
3.2. Treatment
3.2.1. Localised disease at presentation
Ninety-ﬁve of 96 patients with localised disease
underwent surgery. Resection margins were available
in 76/95 (80%): 46/76 patients (61%) had resections with
clear margins (P1 mm, R0), in 30/76 patients (39%)
margins were close or involved (<1 mm, R1).
Forty (42%) patients received radiotherapy (1 deﬁni-
tive, 38 postoperative (PORT), 1 both pre- and postop-
erative). Chemotherapy was administered in 54/95
(57%) patients with resected localised disease: 21/54
(39%) received chemotherapy preoperatively, 30/54
(56%) postoperatively, 3/54 (5%) both. 52/54 patients
(96%) received an anthracycline, 38/54 (70%) also
received alkylating agents.
3.2.2. Metastatic disease at presentation
Seventeen (15%) patients had metastases at diagnosis:
7/17 (42%) pulmonary metastases only, 2/17 (11%) bone
metastases only and 8/17 (47%) had multiple metastatic
sites. Six (35%) underwent anthracycline-based chemo-
therapy, primary resection and metastasectomy. Two
(12%) underwent primary resection, metastasectomy
and PORT. Four (24%) underwent either surgery (3)
or radiotherapy (1) to the primary followed by palliative
anthracycline-based chemotherapy. Five (29%) were
managed with primary resection only (2), radical radio-
therapy (1), palliative anthracycline based chemother-
apy (1). One patient with poor performance status did
not receive any treatment.
3.2.3. Outcome and predictive factors
The median OS was 17 years (95% CI: 10.3–28.6). The
5-years and 10 years estimated survival rates were 70%
and 54%, respectively. The median OS in patients with
localised and metastatic disease at diagnosis was 20r (A), origin and primary site (B).
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tively. The absence of metastases at diagnosis was asso-
ciated with a signiﬁcantly better outcome (P < 0.0001;
hazard ratio (HR) = 0.21; 95% CI: 0.1–0.4). Kaplan–
Meier survival curves are shown in Fig. 2.3.2.4. Outcome in patients with localised disease
Among 95 patients with resected localised disease,
median PFS and OS were 7 (95% CI: 3.0–11.0) and 20
(95% CI: 12.6–27.4) respectively. The 5 and 10 years
OS was 79% and 60%, respectively. Sixteen (16/95;
17%) patients developed local recurrence (LR), managed
with surgery alone in four cases, surgery and PORT in 4,
radiotherapy and chemotherapy in 1, palliative chemo-
therapy in 5 and palliative radiotherapy in 2. Of these
16, 11 patients developed metastatic progression (MP).
One 32-year-old patient, with an extra-skeletal MCS of
the pelvis and multiple peritoneal implants achieved a
prolonged disease stabilisation with trabectedin (12
cycles) after progression on epirubicin and ifosfamide.
Among those developing isolated LR (5/16; 31%) only
one patient died (managed with palliative chemotherapy
due to surgery refusal) while 4 are alive with no evidence
of disease. Thirty-four patients (36%) developed MP
without LR. Among all 45 who developed MP, 28
patients progressed in lung (16/45; 36%) or in bone
(12/45; 26%) only, 17/45 (38%) in multiple sites. Also,
25/45 (55%) recurred within the ﬁrst 2 years from the
surgery, 8/45 (18%) in the 3rd–4th year, 12/45 (27%) at
the 5th year or after. Six (13%) patients developed MP
after 10 years, and one patient progressed with lungFig. 2. Kaplan–Meier survival curve for the overall survival of all patient
(n = 17) and without metastases (n = 96) at diagnosis (P < 0.0001).and bone metastases 20 years after surgery and adjuvant
chemotherapy.
Tissue of origin (P = 0.811), primary site (head and
neck P = 0.968; limbs P = 0.778) and resection margins
(P = 0.442) were not found to inﬂuence the risk of death
in univariate analysis (see Table 1). However, patients
who underwent R1 resection showed a signiﬁcantly
higher risk of LR (1/46, 2% versus 8/30, 27%;
P = 0.002). Chemotherapy administration was associ-
ated with a reduced risk of recurrence (P = 0.046;
HR = 0.482 95% CI: 0.213–0.996) and death
(P = 0.004; HR = 0.445 95% CI: 0.256–0.774). Median
OS was not reached in the chemotherapy group and
was 9 years (95% CI: 3.527–14.473) in the surveillance
group, PFS was 20 years (95% CI: 1.769–38.231) and
4 years (95% CI: 2.070–5.930) respectively. The 5-year
and 10-year OS were 84% and 80% respectively in the
chemotherapy group, 73% and 46% in the surveillance
group. The 5-year and 10-years PFS were 70%, 67%
and 35%, 27%, respectively (Fig. 3). The multivariate
ﬁnal model (Table 2) selected chemotherapy administra-
tion as the only variable predictive of death (P = 0.004;
HR = 0.461 95% CI: 0.328–0.856).
The only patient with localised unresectable disease
at diagnosis was managed with chemotherapy and
radiotherapy, progressed in lungs after 11 months and
died from disease.3.2.5. Outcome in metastatic patients
Only two patients (2/17, 12%) with metastases at pre-
sentation are currently alive. Five of six patients treateds with evaluable data (n = 113) and comparing those with metastases
Table 1
Univariate risk factors aﬀecting survival in mesenchymal chondrosarcoma (MCS) patients with localised at diagnosis (n = 95).
Factors Number evaluable (%) Hazard-ratio (95% conﬁdence interval) P-value
Tissue of origin 95 0.811
 Skeletal 61 (64%) 1.066 (0.630–1.805)
 Extra-skeletal 34 (36%) 1
Primary sites 95
 Head and neck 15 (16%) 1.015 (0.505–2.038) 0.968
 Trunk 43 (45%) 1
 Limbs 37 (39%) 1.102 (0.561–2.168) 0.778
Resection margins 76 0.462
 R0 46 (61%) 0.798 (0.438–1.455)
 R1 30 (39%) 1
Chemotherapy 95 0.004
 Yes 54 (57%) 0.445 (0.256–0.774)
 No 41 (43%) 1
Fig. 3. Kaplan–Meier survival curve for the progression free survival and overall survival of all patients with resected localised disease (n = 95)
comparing those who received chemotherapy (n = 54) and those who underwent surveillance (n = 41).
Table 2
Risk factors aﬀecting survival in mesenchymal chondrosarcoma





 Tissue of origin (skeletal) 1.190 (0.692–2.046) 0.530
 Primary site (limbs) 1.087 (0.551–2.146) 0.810
 Surgical margin (negative) 0.983 (0.422–2.293) 0.969
 Chemotherapy (administered) 0.434 (0.240–0.760) 0.004
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tomy ultimately died of disease. A 52 year-old patient
with extra-skeletal MCS of the thigh and an isolated
spinal metastasis underwent ﬁve cycles of epirubicin
and ifosfamide followed by surgery for both sites andis currently alive and progression free after 1 year. A
14 year-old patient with a skeletal pelvic MCS meta-
static at diagnosis to lungs and mediastinal lymph nodes
managed with radiotherapy and chemotherapy includ-
ing high-dose chemotherapy with stem cell rescue,
remains progression-free after 8 years.
4. Discussion
This series collected from sarcoma reference centres is
the largest reporting on clinical features, management
and outcome for patients with MCS.
Consistent with previous studies, the peak of inci-
dence for MCS is in the 2nd–3rd decade of life, both
genders were equally aﬀected and approximately two-
thirds of all cases primarily aﬀect the skeleton, with
Table 3
Currently available guidelines on the management of mesenchymal chondrosarcoma (MCS).
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of metastases at presentation was found to strongly
inﬂuence survival. Our survival rate is higher compared
with that reported by Cesari et al. or Nakashima et al.
(10-years OS rate 21% and 27%, respectively), though
similar to D’Antonello et al. (67%) [2,9,11]. This may
be explained by the smaller number of patients with
metastases at diagnoses included in this series (15%
and 6%, respectively).
Patients with localised disease at diagnosis treated by
surgery showed the most favourable outcome, with a
median OS of 20 years. Interestingly, the outcome was
favourable also for the small number of patients who
developed isolated LR: among ﬁve patients, four treated
by surgery are still alive and disease free while one, man-
aged with palliative chemotherapy, died. Approximately
half of the patients with localised disease at diagnosis
developed MP, involving lungs or bone in most cases.
Median time to MP has been previously reported in
the range of 18–42 months, with most of the recurrences
occurring within the ﬁrst 5 years [1,2,9,11]. Despite
being more common in the ﬁrst 2 years after diagnosis
(55% of cases in our series), late recurrences are not unu-
sual [1,2]. In the present analysis, 27% of patients pro-
gressed after 5 years, 13% after 10 years and one
patients developed lung metastases after 20 years. These
results, together with those previously reported, argue
for prolonged follow-up.Currently, no reliable predictive factors are available
for localised MCS. Vencio et al. reported a better sur-
vival in patients with MCS of the jaw bones compared
to historical results from unselected series [16]. Con-
versely, Harwood et al. suggested that an axial origin
rather than a peripheral limb location and pain as a pre-
senting symptom could represent unfavourable prognos-
tic factors [17]. Other studies proposed a negative
correlation of hemangiopericytic features, proliferation
rate and extra-skeletal origin with prognosis [1,11,18].
In our series, origin and primary site did not have any
impact on outcome. No data on pathological features
and symptoms have been collected.
Surgery is the mainstay of local treatment with evi-
dence to support improved survival in patients undergo-
ing wide surgical resection [11]. The concomitant use of
radiotherapy and chemotherapy may have a role when
disease is unresectable, although convincing evidence
are still lacking [2,16,19]. In this series, all but one
patient with localised disease at diagnosis underwent
surgery, showing a consistency across the contributing
centres. The incidence of LR was found to be signiﬁ-
cantly higher in patients undergoing surgery with posi-
tive or close margins, suggesting that clear margins
remain an important goal to pursue for patients
with localised disease. Data provided on radiotherapy
were rather incomplete and therefore no comments
can be made regarding its impact on the outcome.
380 A.M. Frezza et al. / European Journal of Cancer 51 (2015) 374–381Chemotherapy administration was associated with a sig-
niﬁcant reduction in the risk of recurrence and death in
patients with localised disease. Prior smaller studies had
suggested a value for chemotherapy in MCS, inﬂuencing
current clinical guidelines, as summarised in Table 3
[9,11,20]. In the retrospective study by Cesari et al., dis-
ease free survival (DFS) in patients between 5 and
10 years after surgical remission of disease was 76% with
chemotherapy and 17% without (P = 0.008) [11]. The
outcome in the series described by D’Antonello et al.,
including 14 young MCS patients with localised disease
most of whom received chemotherapy, also compared
favourably to those previously reported [9]. There is
no consensus regarding the best regimen to be used in
MCS, as also shown by the heterogeneity in the agents
chosen within and across the diﬀerent contributing cen-
tres. In our series, all but two patients treated with che-
motherapy received an anthracycline and most received
alkylating agents, supporting a recommendation for
these agents to be used for (neo-)adjuvant chemotherapy
of MCS in the future.
Due to the small number of enrolled patients, the
incompleteness of the data and the lack of consistency
in treatment approach, recommendations on the man-
agement of patients with metastases cannot be made.
The outcome in patients with metastases at presentation
remains poor and, despite prolonged survival, most will
ultimately die from the disease. Similarly to previous
reports, median OS in our analysis was 3 years
(32.9 months in the series by Cesari et al.) and only
two patients with metastases at diagnosis are still alive.
An aggressive multimodal management did not seem to
be curative (5/6 patients ultimately died from disease).
This study has some limitations, including its retro-
spective nature, the lack of centralised pathology review
and the contribution of multiple centres, which restricts
the amount of data collectable in order to encourage par-
ticipation and accounts for incompleteness. However, we
believe that our ﬁndings together with those previously
reported could represent a valuable starting point to out-
line guidelines in this rare disease, promote a more stand-
ardised approach and encourage an international eﬀort to
include MCS patients in prospective studies, with the
view to further improve outcome in these patients.
4.1. Recommendations for practice
The following recommendations take into account
data from this and previous series and recognise that
further observational studies of current practice are unli-
kely to provide much further insight. By suggesting a
consistent approach to treatment of MCS, the possibil-
ity of future audits by EMSOS may overcome the limi-
tations described and allow ﬁrmer statements to be
made on the eﬀectiveness of interventions. Patients with
MCS should be managed in reference centres. Those
with localised disease should undergo surgery to achieveclear margins and receive (neo-)adjuvant chemotherapy
with doxorubicin and ifosfamide or cisplatin. Follow-up
should take account of the long period during which
patients are at risk of recurrence. Less information is
available about the most appropriate treatment for
patients with metastases at presentation and further
studies are required.Conﬂict of interest statement
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